Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patient Undergoing Laparoscopic Bariatric Surgery
Status:
Completed
Trial end date:
2018-03-31
Target enrollment:
Participant gender:
Summary
Despite the increasing use of patient-controlled anesthesia (PCA) for postoperative pain
management, efforts are continuing to find effective methods to relieve pain after abdominal
surgery. Although opioid is an effective analgesic it has opioid related adverse events
(ORAEs). Bupivacaine should reduce postoperative pain but it has relatively shorter duration
of action. Liposome bupivacaine (Exparel) has been approved as a single dose infiltration for
longer postoperative period analgesic. It provides up to 72 hours analgesia postoperatively;
results in lesser opioids usage and reduce the ORAEs. Transversus abdominis plane (TAP) block
is a relatively new regional anesthetic technique. TAP blocks have been performed to reduce
opioid use and control pain in several laparoscopic surgical procedures, including colorectal
resections, cholecystectomy and bariatric surgery. The aim of this study is to study the
opiate usage, pain and nausea post laparoscopic gastric bypass or sleeve gastrectomy using
Exparel versus Bupivacaine as TAP block and port sites infiltration.